Skip to content
Colorectal Cancer Clinical Trials

Portland, Oregon

Colorectal cancer clinical trials in Portland, OR

40 colorectal cancer studies are recruiting participants at sites in Portland as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Portland at a glance

  • 40 studies are recruiting at a site in Portland.
  • By phase: Phase 1 (9), Phase 1/2 (6), Phase 2 (5), Phase 2/3 (1), Phase 3 (7), No phase (5), Observational (7). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (23), university, hospital or other (17).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Portland

Basic details from each study's public record (the 30 most recently updated of 40). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Oregon Health and Science University
    Registry record
    NCT05863195 · updated
  2. Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT07018869 · updated
  3. Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

    • No phase
    • Ages 45 to 70
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Oregon Health and Science University · Portland VA Medical Center
    Registry record
    NCT05080673 · updated
  4. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Kaiser Permanente Northwest · Legacy Good Samaritan Hospital and Medical Center · Providence Portland Medical Center
    Registry record
    NCT05174169 · updated
  5. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT05334069 · updated
  6. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

    • Observational
    • Ages 40 and older
    • All sexes
    Sponsor
    Adela, Inc
    Study site
    Oregon Health Sciences University
    Registry record
    NCT05366881 · updated
  7. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Wake Forest University Health Sciences
    Study site
    Kaiser Permanente Northwest
    Registry record
    NCT06418204 · updated
  8. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    OHSU Knight Cancer Institute
    Registry record
    NCT07397338 · updated
  9. Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Oregon Health and Science University
    Registry record
    NCT05673148 · updated
  10. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Oregon Health And Science University
    Registry record
    NCT06662786 · updated
  11. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Oregon Health And Science University
    Registry record
    NCT06750094 · updated
  12. Family Communications After Genetic Testing

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT07143487 · updated
  13. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    Providence Cancer Institute
    Registry record
    NCT07542704 · updated
  14. A Study of MGC026 in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    MacroGenics
    Study site
    Providence Cancer Institute
    Registry record
    NCT06242470 · updated
  15. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study site
    Oregon Health & Science University
    Registry record
    NCT04657068 · updated
  16. A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Compass Oncology - Rose Quarter /ID# 280127
    Registry record
    NCT07525206 · updated
  17. A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Northwest Cancer Specialists /ID# 275151
    Registry record
    NCT07023289 · updated
  18. Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Kaiser Permanente Interstate Medical Office Central
    Registry record
    NCT07222800 · updated
  19. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    Oregon Health and Science University
    Registry record
    NCT05919264 · updated
  20. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study site
    Oregon Health & Science University (OHSU)
    Registry record
    NCT04585750 · updated
  21. Colonoscopy vs Stool Testing for Older Adults With Colon Polyps

    • No phase
    • Ages 65 to 82
    • All sexes
    Sponsor
    Dartmouth-Hitchcock Medical Center
    Study site
    Oregon Health & Science University (Knight Cancer Institute)
    Registry record
    NCT05612347 · updated
  22. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #51
    Registry record
    NCT05176483 · updated
  23. A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    ALX Oncology Inc.
    Study site
    ALX Center 6
    Registry record
    NCT07085091 · updated
  24. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT05877599 · updated
  25. A Study of PHN-012 in Patients With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pheon Therapeutics
    Study site
    PHN-012-001 Site
    Registry record
    NCT07127874 · updated
  26. Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    OHSU Knight Cancer Institute
    Study site
    OHSU Knight Cancer Institute
    Registry record
    NCT05081024 · updated
  27. A Phase 1/1b Study of IAM1363 in HER2 Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    Providence Cancer Institute
    Registry record
    NCT06253871 · updated
  28. Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

    • Phase 1
    • Ages 12 to 85
    • All sexes
    Sponsor
    Inhibrx Biosciences, Inc
    Study site
    Oregon Health & Science University
    Registry record
    NCT03715933 · updated
  29. A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Providence Cancer Center Oncology and Hematology Care- Eastside
    Registry record
    NCT04895709 · updated
  30. Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    MOMA Therapeutics
    Registry record
    NCT06974110 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Portland, OR on ClinicalTrials.gov.

Ask about studies near Portland

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call